These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
562 related articles for article (PubMed ID: 28734778)
1. Diagnostic value of Kassem TW; Abdelaziz O; Emad-Eldin S Diagn Interv Imaging; 2017 Oct; 98(10):693-698. PubMed ID: 28734778 [TBL] [Abstract][Full Text] [Related]
2. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631 [TBL] [Abstract][Full Text] [Related]
3. Role of Albano D; Zizioli V; Treglia G; Odicino F; Giubbini R; Bertagna F Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):10-16. PubMed ID: 30396849 [TBL] [Abstract][Full Text] [Related]
4. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma. Dancheva Z; Bochev P; Chaushev B; Yordanova T; Klisarova A Nucl Med Rev Cent East Eur; 2016; 19(1):22-7. PubMed ID: 26841376 [TBL] [Abstract][Full Text] [Related]
5. The impact of Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. Lucas JD; O'Doherty MJ; Wong JC; Bingham JB; McKee PH; Fletcher CD; Smith MA J Bone Joint Surg Br; 1998 May; 80(3):441-7. PubMed ID: 9619933 [TBL] [Abstract][Full Text] [Related]
7. Functional image in soft tissue sarcomas: An update of the indications of Rodríguez-Alfonso B; Simó-Perdigó M; Orcajo Rincón J Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):233-243. PubMed ID: 32616457 [TBL] [Abstract][Full Text] [Related]
8. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613 [TBL] [Abstract][Full Text] [Related]
9. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344 [TBL] [Abstract][Full Text] [Related]
10. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma. Liu Y Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435 [TBL] [Abstract][Full Text] [Related]
12. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review. Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981 [TBL] [Abstract][Full Text] [Related]
13. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135 [TBL] [Abstract][Full Text] [Related]
14. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities. Salem SS; Shahin MA Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387 [TBL] [Abstract][Full Text] [Related]
15. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma. Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients. Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023 [TBL] [Abstract][Full Text] [Related]
17. A retrospective study comparing contrast-enhanced computed tomography with 18F-FDG-PET/CT in the early follow-up of patients with retroperitoneal sarcomas. Niccoli-Asabella A; Altini C; Notaristefano A; Merenda N; Altieri ML; Stabile-Ianora AA; Fanelli M; Rubini G Nucl Med Commun; 2013 Jan; 34(1):32-9. PubMed ID: 23111380 [TBL] [Abstract][Full Text] [Related]
18. Integrated 18F-FDG PET/MRI compared to MRI alone for identification of local recurrences of soft tissue sarcomas: a comparison trial. Erfanian Y; Grueneisen J; Kirchner J; Wetter A; Podleska LE; Bauer S; Poeppel T; Forsting M; Herrmann K; Umutlu L Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1823-1831. PubMed ID: 28567495 [TBL] [Abstract][Full Text] [Related]
19. FDG-avid presacral soft tissue mass in previously treated rectal cancer: Diagnostic outcome and additional value of MRI, including diffusion-weighted imaging. Pennings JP; de Haas RJ; Murshid KJA; de Jong KP; Dierckx RAJO; Kwee TC Eur J Surg Oncol; 2019 Apr; 45(4):606-612. PubMed ID: 30594404 [TBL] [Abstract][Full Text] [Related]